Search Site

Trends banner

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Equinor signs $27 bn gas deal

The 10-year contract was signed with Centrica.

ADNOC Drilling secures $1.15bn contract

The contract for two jack-up rigs begins in the second quarter.

AstraZeneca Q3 profit swells

Total revenues gained five percent to $33.8 billion despite a $2.9-billion slump in revenue from Covid treatments. (AFP)
  • Net profit soared almost 90 percent to $1.26 billion in the three months to the end of September compared with a year earlier
  • While overall sales grew, revenue from its Covid jab Vaxzevria slumped 98 percent in the first nine months of the year compared with the same part of 2022

London, United Kingdom – British pharmaceuticals giant AstraZeneca said Thursday that third-quarter net profit nearly doubled on solid demand for cancer treatments, despite evaporating sales of Covid medicines.

Net profit soared almost 90 percent to $1.26 billion in the three months to the end of September compared with a year earlier, the Covid-vaccine maker said in a statement.

Total revenues gained five percent to $33.8 billion despite a $2.9-billion slump in revenue from Covid treatments.

The group was boosted by a 20-percent jump in sales of oncology drugs.

“Our company continued its strong growth trajectory in the third quarter,” said chief executive Pascal Soriot.

While overall sales grew, revenue from its Covid jab Vaxzevria slumped 98 percent in the first nine months of the year compared with the same part of 2022.

AstraZeneca also lifted its annual revenue guidance, sending its share price climbing 2.8 percent to almost £105 in morning deals on London’s top-tier FTSE 100 index, which was flat overall.